PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 17, 2026Clinica Chimica Acta1 citationsOpen Access

Holotranscobalamin-based algorithm for the identification of macro-vitamin B12 in analytical hypercobalaminemia

View Full Paper
PFPatricia Fernández-TomásLRLeyre RuizEAEstíbaliz Alegre

Key Points

  • To assess the impact of vitamin B12 macrocomplexes on holotranscobalamin immunoassay performance in detecting hypercobalaminemia.
  • Collected 528 serum samples from adults, classifying them as HyperB12 or NormoB12.
  • Measured total B12 and holotranscobalamin (HoloTC) using immunoassays and characterized M-B12 presence based on B12 recovery after PEG precipitation.
  • Compared HoloTC concentrations across different sample groups to evaluate assay performance.
  • M-B12 was detected in 16.0% of HyperB12 samples and none in NormoB12.
  • HoloTC was higher in M-HyperB12 compared to NoM-HyperB12 (median 300 pmol/L vs 120 pmol/L).
  • HoloTC identified M-B12 presence with 75.0% sensitivity and 95.1% specificity at 201 pmol/L (AUC 0.870).

Abstract

Interference by vitamin B12 (B12) macrocomplexes is common but underappreciated in clinical practice. When unexpected hypercobalaminemia is detected, analytical interference must be considered. Holotranscobalamin (HoloTC) reflects the biologically active B12 fraction, but the impact of B12 macrocomplexes (M-B12) on HoloTC immunoassay performance remains unclear. We collected 528 adult serum samples. Total B12 and HoloTC were measured by commercial immunoassays. M-B12 presence was defined as B12 recovery after polyethylene glycol precipitation (PEG) <50%. Samples were classified as HyperB12 (hypercobalaminemia) or NormoB12. M-B12 was detected in 16.0% (66/411) of HyperB12 samples but in none of NormoB12. In three M-B12 cases, B12 fell below the lower reference limit after PEG. B12 recovery was higher in NormoB12 than in NoM-HyperB12 ( p < 0.001). HoloTC was measured in a subgroup of samples (NormoB12 n = 16; NoM-HyperB12 n = 41; M-HyperB12 n = 40). HoloTC was higher in M-HyperB12 (median 300 pmol/L) than in NoM-HyperB12 (median 120 pmol/L), while NormoB12 did not differ from NoM-HyperB12. After PEG precipitation, HoloTC recovery was lower than B12 recovery in HyperB12 samples (NoM-HyperB12: 29.8% vs 73.1%; M-HyperB12: 11.0% vs 27.5%), whereas the difference was not significant in NormoB12 (62.9% vs 83.5%). B12 and HoloTC concentrations showed correlation before ( r = 0.45, p = 0.004) and after PEG ( r = 0.52, p < 0.001) precipitation only in M-B12 group. HoloTC identified M-B12 presence (AUC 0.870) with 75.0% sensitivity and 95.1% specificity at 201 pmol/L. HoloTC concentrations are influenced by the presence of B12 macrocomplexes. The HoloTC assay may serve as a biomarker to screen for M-B12 in patients with analytical HyperB12. • Macro-B12 found in 16% of hypercobalaminemia; absent in normo-B12. • HoloTC polyethylene glycol recovery was lower than B12 recovery in HyperB12. • HoloTC detected macro-B12 (AUC 0.870); cutoff 201 pmol/L (Se 75.0%, Sp 95.1%). • HoloTC-first algorithm may reduce manual PEG precipitation in hypercobalaminemia.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Fernández-Tomás et al. (2026) studied this question.

synapsesocial.com/papers/6a095bdd7880e6d24efe1b43https://doi.org/10.1016/j.cca.2026.121085
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Challenges in the diagnosis of hypervitaminemia B12. Interference by immunocomplexes2023 · 13 citations
  2. 2Polyethylene glycol precipitation: proceed with care2008 · 87 citations
  3. 3Circulating antibody to transcobalamin II causing retention of vitamin B12 in the blood1977 · 40 citations
  4. 4Markedly Increased Vitamin B12 Concentrations Attributable to IgG–IgM–Vitamin B12 Immune Complexes2006 · 45 citations
  5. 5Determination of serum holotranscobalamin concentrations with the AxSYM active B12 assay: cut-off point evaluation in the clinical laboratory2009 · 32 citations